Eli Lilly (LLY)

Eli Lilly's nuclear move signals a shift beyond AI, as industrial giants like Nucor and Dow turn to reactors for reliable, 24/7 power.

Regulators approved the company's GLP-1 weight loss pill, Foundayo, at the beginning of April.

Eli Lilly said Monday it will spend up to $7 billion to buy privately held Kelonia Therapeutics for its suite of cancer drugs.

Eli Lilly currently trades at $926.10 and has been a dream stock for shareholders. It’s returned 386% since April 2021, blowing past the S&P 500’s 70.2% gain...

No need for a time machine to profit from these companies.

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.

One is a behemoth, the other is a minnow, but both have promising opportunities in the GLP-1 space.

The company's recent dip may be a buying opportunity.

Eli Lilly obesity pill logs 1,390 U.S. scripts in first week, trailing Novo's oral Wegovy as competition in weight-loss drugs intensifies.

Eli Lilly's oral weight-loss drug, Foundayo, nabbed 1,390 prescriptions in its first week on the market, analysts said Friday.

The stock could have plenty of room to run from current levels.

These companies boast significant upside potential.

There are other factors to consider before investing in this -- or any other -- healthcare company.

It's acquiring an asset with a very promising lead drug candidate.

MeiraGTx reacquires bota-vec from Johnson & Johnson, outlining regulatory plans, funding outlook, and updated xerostomia data.

Eli Lilly Foundayo shows cardiovascular safety and stronger A1C, weight reduction, while the FDA flags liver risk, seeks additional data.

Lilly's revenue has soared thanks to its obesity drugs.

And can Novo Nordisk catch up to its rival in the weight loss market?

During the last market crash, these stocks all generated positive returns -- one as high as 80%.

As of April 15, 2026, the biotechnology sector is witnessing a paradigm shift in precision oncology, spearheaded by Revolution Medicines, Inc. (Nasdaq: RVMD). Once considered a high-risk clinical-stage venture, RVMD has transformed into a late-stage powerhouse following a series of high-stakes clinical successes. The company is currently in the spotlight after a "watershed moment" on [...]

AbbVie is making progress in this market, but it is still far behind the leader.

What Happened? Shares of cloud computing and online retail behemoth Amazon (NASDAQ:AMZN) jumped 3.6% in the afternoon session after the company announced it ...